Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.
Clinical pharmacokinetics February 1, 2025 K V van der Heijden, M E Otto, J W Schoones et al. 7 citations
A systematic review of 13 publications covering eight datasets found that the pharmacokinetics of DMT in humans have been characterized only to a limited extent. All studies administered DMT intravenously except one intramuscular injection. DMT is rapidly metabolized to indole-3-acetic acid (IAA), with a half-life of 4.8–19.0 minutes and clearance of 8.1–46.8 L/min. It shows extensive tissue redistribution, indicated by a high terminal volume of distribution (123–1084 L). High variability in dose-normalized exposure and differences between bolus and infusion administration were observed. Publications often lack details on demographics, absolute doses, and pharmacokinetic parameters, highlighting the need for further studies.